Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 2 | 2017 | 29 | 0.290 |
Why?
|
| Lymphoma | 2 | 2019 | 323 | 0.250 |
Why?
|
| MicroRNAs | 3 | 2017 | 838 | 0.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 184 | 0.210 |
Why?
|
| Germinal Center | 3 | 2017 | 37 | 0.200 |
Why?
|
| Lymph Nodes | 3 | 2017 | 376 | 0.190 |
Why?
|
| Hyalin | 2 | 2017 | 6 | 0.190 |
Why?
|
| Castleman Disease | 2 | 2017 | 14 | 0.180 |
Why?
|
| Orbital Neoplasms | 2 | 2019 | 65 | 0.180 |
Why?
|
| Antigens, CD20 | 2 | 2017 | 37 | 0.170 |
Why?
|
| RNA, Viral | 3 | 2017 | 540 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 61 | 0.160 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 30 | 0.150 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2017 | 2 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1227 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 517 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 320 | 0.140 |
Why?
|
| Genes, myc | 2 | 2012 | 99 | 0.120 |
Why?
|
| Viral Load | 1 | 2017 | 382 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 2 | 2015 | 663 | 0.120 |
Why?
|
| Marek Disease | 1 | 2014 | 2 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1424 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2017 | 280 | 0.120 |
Why?
|
| Breast Implants | 1 | 2013 | 28 | 0.110 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 44 | 0.110 |
Why?
|
| Lymphocytosis | 1 | 2013 | 14 | 0.110 |
Why?
|
| Viral Proteins | 1 | 2015 | 348 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1711 | 0.110 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 129 | 0.100 |
Why?
|
| Blast Crisis | 1 | 2011 | 17 | 0.090 |
Why?
|
| Mastocytosis, Systemic | 1 | 2011 | 7 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 300 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 248 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 137 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 293 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 99 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 96 | 0.090 |
Why?
|
| Middle Aged | 11 | 2019 | 25655 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2011 | 146 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 645 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 137 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2017 | 757 | 0.080 |
Why?
|
| Aged | 9 | 2019 | 18799 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 375 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 525 | 0.070 |
Why?
|
| Immunophenotyping | 3 | 2017 | 333 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6293 | 0.060 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2004 | 2 | 0.060 |
Why?
|
| Adult | 8 | 2019 | 28764 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 474 | 0.060 |
Why?
|
| Biopsy | 2 | 2019 | 1249 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 65 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12049 | 0.060 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2002 | 7 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2002 | 7 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 872 | 0.050 |
Why?
|
| Male | 10 | 2019 | 59559 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1677 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 2373 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2481 | 0.050 |
Why?
|
| Humans | 15 | 2019 | 122349 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1008 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 325 | 0.040 |
Why?
|
| Gene Rearrangement | 2 | 2012 | 316 | 0.040 |
Why?
|
| Female | 9 | 2019 | 64923 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5013 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 114 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 49 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1872 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 246 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1678 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 4643 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2011 | 318 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2015 | 32 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2015 | 60 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 812 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 810 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 515 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 802 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 109 | 0.030 |
Why?
|
| Brachial Plexus | 1 | 2014 | 19 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 758 | 0.030 |
Why?
|
| Birds | 1 | 2014 | 85 | 0.030 |
Why?
|
| Reed-Sternberg Cells | 1 | 2013 | 7 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2013 | 11 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 23 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2013 | 29 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 4490 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 141 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 63 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 87 | 0.030 |
Why?
|
| Time Factors | 2 | 2013 | 6182 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 1076 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 137 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2014 | 83 | 0.030 |
Why?
|
| Microvessels | 1 | 2013 | 56 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 301 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 285 | 0.030 |
Why?
|
| Breast | 1 | 2013 | 214 | 0.030 |
Why?
|
| Device Removal | 1 | 2013 | 223 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2080 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 338 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 212 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 267 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 34 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 53 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 58 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 1131 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 712 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1296 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2799 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 419 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1407 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 548 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1579 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1992 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2004 | 9 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2004 | 217 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 8775 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1674 | 0.010 |
Why?
|
| United States | 1 | 2019 | 10494 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3448 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 15858 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1592 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 503 | 0.010 |
Why?
|
| Chromatin | 1 | 2002 | 552 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 33730 | 0.010 |
Why?
|